TNFRSF17 and neutropenia: Neutropenia, lymphopenia and hypogammaglobulinemia secondary to B-cell aplasia can be seen; as BCMA is expressed on healthy plasma cells as well as MM cells, BCMA-targeting therapies can have on-target off-tumour effects and thus deplete the B-cell reservoir, increasing infection risk [98].